Avidicure is pioneering an entirely new multifunctional antibody modality, branded AVC-Boosters, with broad applicability in oncology. The AVC-Boosters are dual agonistic, multifunctional and avidity-engineered antibodies designed to elicit orchestrated innate and adaptive immune responses as targeted cancer monotherapies. The company leverages a fully owned proprietary platform combining decades of antibody engineering, in silico protein design capabilities, and immunology expertise. Through AVC-Booster plug-and-play functionality, multiple products can be developed from the platform. Avidicure's lead product, AVC-S-101, is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple other indications. The founding management team is led by CEO Arthur Lahr, with Dirk De Naeyer (COO), Robert Friesen (CSO) and Govert Schouten (CBO). Avidicure raised $50m in seed financing to advance its programs; no operating metrics were reported in the article.

Total raised

$50M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2025